Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can inhaled nitric oxide speed pneumonia recovery?

NCT ID NCT06170372

Disease control Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial investigates whether adding high-dose inhaled nitric oxide to standard antibiotics can help people with pneumonia recover faster. The study includes 200 adults with hospital-acquired or community-acquired pneumonia. Participants receive either nitric oxide or a sham treatment three times daily for up to seven days, and researchers track how quickly pneumonia resolves and how the heart and lungs respond.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inhaled nitric oxide at 200 ppm
What this could lead to
If it works, this could offer a simple add-on therapy to help people recover faster from pneumonia and reduce strain on the heart and lungs.
What could go wrong
This is an early-stage trial with no prior proof of benefit in pneumonia. High-dose nitric oxide can affect blood oxygen levels and must be carefully monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. An established diagnosis of Nosocomial Pneumonia (NP) after cardiac surgery under cardiopulmonary bypass (CPB) or hospitalization for Community-acquired pneumonia (CAP). 2. Spontaneous breathing. 3. Age \> 18 years. 4. Signed informed consent. 5. Negative result of immunochromatographic Severe acute respiratory syndrome-related coronavirus 2 rapid antigen test on the day of diagnosis of pneumonia. Diagnostic criteria for NP The diagnosis of NP is considered established when the number of points on the Clinical Pulmonary Infection Score (CPIS) is greater than 6: Diagnostic criteria for CAP: Radiologically confirmed focal pulmonary opacity and at least 2 clinical symptoms and signs of the following: 1. acute fever at the onset of the disease (t° \> 38.0°C); 2. cough with sputum; 3. physical signs (crepitus/fine rales, bronchial breathing, shortening of percussion sound); 4. leukocytosis \> 10x109/l and/or left shift (\> 10%) Exclusion Criteria: 1. Diagnosed infectious process of another localization (surgical site infection (SSI), acute and chronic urinary tract infection (active), catheter-related bloodstream infection, peritonitis, infective endocarditis etc.). 2. Mechanical ventilation 3. Presence of tracheostomy 4. Patient's participation in another clinical trial at the time of screening or within the previous 3 months. 5. Concomitant pulmonary disease with the need for respiratory support before the development of pneumonia. 6. History of malignancy or other irreversible diseases/conditions with a life expectancy of less than 1 year. 7. Presence of HIV infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community-acquired pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia Healthcare-Associated Pneumonia nosocomial infection pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Community-acquired pneumonia Nosocomial pneumonia

Contacts and locations

Locations

  • Cardiology Research Institute Tomsk National Research Medical Center

    Tomsk, Select..., 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.